Profile data is unavailable for this security.
About the company
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.
- Revenue in USD (TTM)1.96bn
- Net income in USD312.32m
- Incorporated2014
- Employees5.80k
- LocationMedpace Holdings Inc5375 Medpace WayCINCINNATI 45227-1543United StatesUSA
- Phone+1 (513) 579-9911
- Fax+1 (302) 655-5049
- Websitehttps://investor.medpace.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Repligen Corp | 638.76m | 41.58m | 9.30bn | 1.78k | 231.13 | 4.71 | 84.82 | 14.56 | 0.7207 | 0.7207 | 11.27 | 35.35 | 0.2388 | 1.47 | 5.31 | 358,252.40 | 1.55 | 4.38 | 1.74 | 5.03 | 49.35 | 55.43 | 6.51 | 15.91 | 5.75 | -- | 0.2272 | 0.00 | -20.31 | 26.91 | -77.64 | 20.13 | 24.99 | -- |
| BIO-TECHNE Corp | 1.14bn | 224.12m | 10.07bn | 3.05k | 46.21 | 5.13 | 30.11 | 8.79 | 1.39 | 1.39 | 7.09 | 12.50 | 0.4495 | 2.21 | 5.84 | 375,409.50 | 8.80 | 9.57 | 9.28 | 10.20 | 67.13 | 67.35 | 19.58 | 21.91 | 3.03 | 18.86 | 0.1854 | 24.19 | 2.81 | 12.07 | 4.88 | 25.13 | 12.81 | 0.00 |
| Catalent Inc | 4.10bn | -1.30bn | 10.12bn | 17.80k | -- | 2.75 | -- | 2.47 | -7.18 | -7.18 | 22.52 | 20.37 | 0.3878 | 4.09 | 3.00 | 230,224.70 | -12.32 | 2.88 | -14.02 | 3.26 | 17.94 | 31.03 | -31.77 | 6.35 | 1.71 | -0.625 | 0.5758 | 0.00 | -11.22 | 11.59 | -153.00 | -- | 26.69 | -- |
| Exact Sciences Corp | 2.50bn | -204.15m | 10.68bn | 6.50k | -- | 3.39 | 4,344.49 | 4.27 | -1.14 | -1.14 | 13.81 | 17.34 | 0.3937 | 5.32 | 13.82 | 384,579.40 | -3.22 | -9.71 | -3.47 | -10.60 | 73.83 | 74.10 | -8.17 | -28.21 | 2.07 | -- | 0.4311 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
| United Therapeutics Corporation | 2.33bn | 984.80m | 11.00bn | 1.17k | 11.80 | 1.84 | 10.60 | 4.73 | 19.82 | 19.82 | 46.83 | 127.23 | 0.3523 | 2.41 | 9.32 | 1,992,723.00 | 14.91 | 10.38 | 16.33 | 11.27 | 88.94 | 91.47 | 42.31 | 29.25 | 4.28 | -- | 0.1047 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
| Natera Inc | 1.08bn | -434.80m | 11.20bn | 3.28k | -- | 14.32 | -- | 10.35 | -3.80 | -3.80 | 9.41 | 6.40 | 0.7634 | 15.49 | 4.14 | 329,851.00 | -30.66 | -36.17 | -39.20 | -46.60 | 45.52 | 45.88 | -40.16 | -56.15 | 3.96 | -- | 0.3219 | -- | 31.99 | 33.26 | 20.63 | -- | 58.81 | -- |
| Incyte Corp | 3.70bn | 597.60m | 11.60bn | 2.52k | 19.55 | 2.23 | 17.06 | 3.14 | 2.64 | 2.64 | 16.36 | 23.14 | 0.5855 | 4.43 | 5.32 | 1,464,203.00 | 9.47 | 9.07 | 11.69 | 11.02 | 93.71 | 94.97 | 16.17 | 13.68 | 3.69 | -- | 0.0062 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.13bn | 474.62m | 11.80bn | 20.00k | 24.82 | 3.27 | 14.85 | 2.86 | 9.23 | 9.23 | 80.25 | 70.06 | 0.5228 | 8.19 | 5.39 | 206,470.50 | 6.08 | 6.46 | 7.09 | 7.62 | 36.89 | 36.99 | 11.63 | 11.58 | 1.16 | 4.97 | 0.4203 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
| Sarepta Therapeutics Inc | 1.24bn | -535.98m | 12.09bn | 1.31k | -- | 14.05 | -- | 9.72 | -6.15 | -6.15 | 13.46 | 9.17 | 0.389 | 0.5708 | 4.04 | 946,222.30 | -16.77 | -21.63 | -20.94 | -25.75 | 87.91 | 86.65 | -43.11 | -77.05 | 3.45 | -- | 0.5903 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
| Medpace Holdings Inc | 1.96bn | 312.32m | 12.27bn | 5.80k | 40.34 | 18.23 | 36.09 | 6.25 | 9.81 | 9.81 | 61.73 | 21.72 | 1.23 | -- | 7.31 | 332,680.00 | 19.58 | 13.94 | 46.20 | 23.18 | 27.99 | 28.84 | 15.92 | 15.23 | -- | -- | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
| Neurocrine Biosciences, Inc. | 1.89bn | 249.70m | 13.68bn | 1.40k | 55.93 | 6.01 | 50.47 | 7.25 | 2.43 | 2.43 | 18.84 | 22.61 | 0.6716 | 1.08 | 4.78 | 1,347,929.00 | 8.89 | 9.77 | 11.28 | 12.19 | 97.90 | 98.51 | 13.23 | 14.79 | 2.40 | -- | 0.0708 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
| Viatris Inc | 15.43bn | 54.70m | 13.74bn | 38.00k | 273.33 | 0.6788 | 4.92 | 0.8907 | 0.0423 | 0.0423 | 12.81 | 17.05 | 0.3158 | 2.49 | 5.09 | 405,971.10 | 0.112 | 0.0887 | 0.1315 | 0.1061 | 43.64 | 40.29 | 0.3546 | 0.2891 | 1.22 | 2.79 | 0.4696 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
Data as of Apr 26 2024. Currency figures normalised to Medpace Holdings Inc's reporting currency: US Dollar USD
30.29%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.52m | 8.19% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 2.16m | 7.02% |
| Wasatch Advisors, Inc.as of 31 Mar 2024 | 974.42k | 3.17% |
| Riverbridge Partners LLCas of 31 Dec 2023 | 683.94k | 2.22% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 671.15k | 2.18% |
| Geode Capital Management LLCas of 31 Dec 2023 | 492.93k | 1.60% |
| Boston Trust Walden, Inc.as of 31 Dec 2023 | 488.27k | 1.59% |
| TD Asset Management, Inc.as of 31 Dec 2023 | 467.04k | 1.52% |
| Fuller & Thaler Asset Management, Inc.as of 31 Dec 2023 | 444.74k | 1.45% |
| Wellington Management Co. LLPas of 31 Dec 2023 | 414.57k | 1.35% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
